What are the Zacks Style Scores? Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. The Zac ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

Henry Schein (HSIC) recently extended its existing partnership with Special Olympics through 2025 to support health screening and education for its athletes at select events around the world. Through the collaboration, the company donates essential oral health and medical care products for the Special Olympics Healthy Athletes program in Australia, Canada, Germany, the United Kingdom and the United States. The donations to Special Olympics Healthy Athletes are an initiative of Henry Schein Cares, HSIC's glo ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What ar ...

| --- | --- | --- | --- | |--------------------------------------------|---------|---------|-------| | (in millions of USD) | Q1 2024 | Q1 2023 | y/y ∆ | | Global Technology/VAS | $217 | $191 | 13.8% | | Global Dental Specialties* | 284 | 233 | 21.6% | | Global Technology/VAS + Dental Specialties | $501 | $424 | 18.1% | | | | | | 17 18 19 Q1 2024 Financial Highlights Q1 2023 Q1 2024 Growth Q1 2023 Q1 2024 Growth Net Sales $ 3,060 $ 3,172 3.7% $ 3,060 $ 3,172 3.7% Operating Income 175 150 -14.6% $ 15 235 225 ...

Financial Data and Key Metrics - Global sales for Q1 2024 were $3.2 billion, with a sales growth of 3.7% and LCI sales decreased by 1.8% [24] - Non-GAAP net income for Q1 2024 was $143 million or $1.10 per diluted share, compared to $161 million or $1.21 per diluted share in the prior year [25] - Operating cash flow for Q1 2024 was $197 million, compared to $27 million last year, driven by a reduction in receivable balances [41] - Adjusted EBITDA for Q1 2024 was $255 million, consistent with Q1 2023 [88] - Gross margin improved by 32 basis points, primarily due to contributions from businesses acquired in 2023 [61] Business Line Performance - Global Dental sales were $1.9 billion, with sales growth of 0.8% and LCI sales decreased by 2.9% [88] - Dental specialty product sales were $284 million, with growth of 21.6% driven by acquisitions and low single-digit organic growth in implants and endodontics [34] - Global Medical sales were $1.0 billion, with sales growth of 7.3% and LCI sales decreased by 0.7% [49] - Technology and value-added services sales were $217 million, with total sales growth of 13.8% [38] Market Performance - North American Dental equipment LCI sales grew 2.9%, while international equipment sales decreased by 3.8% [48] - CAD/CAM equipment grew nicely globally, with pricing on intraoral scanners stabilizing [34] - Germany showed positive trends in equipment sales, driven by technical service [48] - The U.S. THRIVE Signature program added 2,000 new members in Q1, bringing the total to approximately 5,000 [18] Strategic Direction and Industry Competition - The company is focusing on high-growth, high-margin businesses, with 40.9% of non-GAAP operating income coming from these areas in Q1 [49] - New product launches, such as the Easy 2.0 implant system in Germany and the upcoming BioHorizons implant system in the U.S., are expected to expand market share [37] - The company is integrating recent acquisitions, including Biotech and S.I.N, which will contribute to internal growth starting in Q2 [8] - The BOLD+1 strategic plan is driving growth, with a focus on innovation in dental implants, endodontics, and orthodontics [54] Management Commentary on Operating Environment and Future Outlook - The company expects sales growth to be more significant in the back half of 2024, driven by recovery from the cyber incident and new product launches [91] - Management remains optimistic about the dental and medical markets, with stable patient traffic and a shift of procedures from acute care to alternate care settings [32] - The company is confident in its ability to regain market share and improve growth in Q3 and Q4 [30] Other Important Information - The cyber incident reduced sales growth by approximately 300 to 400 basis points in Q1 [24] - The company repurchased approximately 1 million shares of common stock in Q1 at an average price of $75.10 per share [62] - The company is in the process of filing a cyber insurance claim, with a $60 million claim limit and a $5 million retention [51] Q&A Session Summary Question: Gross margin drivers and sustainability [96] - The gross margin improvement was driven by a mix of high-growth, high-margin businesses and recovery in distribution margins [104][71] - The company expects gross margins to remain strong, supported by ongoing recovery in distribution businesses and contributions from recent acquisitions [103] Question: Dental equipment growth and market trends [72] - Dental equipment sales were impacted by a pause in Q4 due to the cyber incident, but the market has stabilized, with traditional equipment sales consistent with last year [73] - CAD/CAM equipment is performing well, with pricing stabilized and no significant discounting [73] Question: Implant market growth and market share [76] - The company is not significantly impacted by price sensitivity in the implant market, as it is positioned as a discounter of premium products [77] - New product launches, such as the Easy 2.0 in Germany and the upcoming BioHorizons implant in the U.S., are expected to expand market share [78][79] Question: Revenue growth cadence and expectations [91] - The company expects stronger growth in the back half of 2024, driven by recovery from the cyber incident and new product launches [91] Question: Impact of the Change Healthcare cyber incident on technology sales [113] - The Change Healthcare cyber incident caused a stagnation in technology sales in March, but the company expects growth to normalize in Q2 [114] - The company successfully processed claims through an alternative provider within 48 hours, which was well-received by customers [116] Question: Medical distribution competitive landscape [118] - The company is not significantly impacted by competitive pressures in the medical distribution market, with strong performance in alternate care settings [118] Question: North American dental consumables performance [119] - North American dental consumables sales were down 5%, with a 300-400 basis point impact from the cyber incident [119] - Pricing in the dental market is relatively stable, with some movement towards corporate brands [120] Question: SG&A cadence and cost restructuring [127] - SG&A was higher in Q1 due to the integration of higher-margin businesses, with expectations for continued consistency in future quarters [128] Question: Home health growth opportunities [130] - The company is optimistic about its Home Solutions business, which is approaching $350 million annually and expected to grow organically [131] Question: Dental market skepticism and challenges [133] - The dental market is stable, with seasonal impacts in Q1, but overall leaning towards growth [134] - The company is well-positioned to navigate challenges, with a focus on innovation and customer support [137]

For the quarter ended March 2024, Henry Schein (HSIC) reported revenue of $3.17 billion, up 3.7% over the same period last year. EPS came in at $1.10, compared to $1.21 in the year-ago quarter.The reported revenue represents a surprise of -1.76% over the Zacks Consensus Estimate of $3.23 billion. With the consensus EPS estimate being $0.99, the EPS surprise was +11.11%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Henry Schein, Inc. (HSIC) registered adjusted earnings per share (EPS) of $1.10 in the first quarter of 2024, down 9.1% from the year-ago period’s adjusted EPS. However, the metric exceeded the Zacks Consensus Estimate by 11.1%.Revenues in DetailHenry Schein reported net sales of $3.17 billion in the first quarter, up 3.7% year over year. The metric lagged the Zacks Consensus Estimate by 1.8%. The year-over-year upside reflects an internal sales decline of 1.8%.On a geographic basis, the company recorded sa ...

Henry Schein (HSIC) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this health care products maker would post earnings of $0.70 per share when it actually produced earnings of $0.66, delivering a surprise of -5.71%.Over the last four quarte ...

FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SOLID FIRST-QUARTER 2024 FINANCIAL RESULTS AND UPDATES 2024 FINANCIAL GUIDANCE ● First-quarter 2024 sales growth of 3.7%, GAAP diluted EPS of $0.72 and non-GAAP diluted EPS of $1.10 ● Tightens total sales growth guidance range to 8% to 10%, reflecting continued recovery from last year's cyber incident and a strong pipeline of new specialty products and software innovation ● Affirms 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16 and 2024 Adjusted EBITDA growth ...